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platelet production, resulting in low platelet counts (thrombocytopenia). 
Romiplostim has shown efficacy in increasing platelet counts. The objective  
of this study was to conduct meta-analysis and present total evidence  
for Romiplostim for treatment of ITP. METHODS: For this meta-analysis we 
included randomized controlled trials (RCTs) evaluating Romiplostim for the 
treatment of ITP. We included RCTs that compared romiplostim versus placebo 
for management of ITP, had a treatment duration of at least 24 weeks,  
were doubleblind (patients and investigators blinded) and reported data  
on platelet response. A systematic literature search for Etanercept trials  
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar,  
and Cochrane. Data was collected for the study size, interventions, year, and the 
two outcomes overall and durable platelet response rate. For meta-analysis, 
random effects and fixed effects models were used to obtain cumulative 
statistics. RESULTS: Two RCTs with a total of 125 patients were identified.  
The pooled response rates for Romiplostim for overall platelet response  
rate were 82% (95% CI 73%-90%); and for durable platelet response rate were 48% 
(95% CI 26%-71%). The pooled response rates for placebo for overall platelet 
response rate were 7% (95% CI 0%-15%), and for durable platelet response rate 
were 2% (95% CI 0%-4%). For overall platelet response rate the cumulative 
relative risk with Romiplostim versus placebo was 0.09 (95% CI 4%-14%). For 
durable platelet response rate, the cumulative relative risk with Romiplostim 
versus placebo was 0.03 (95% CI 0%-6%). CONCLUSIONS: Meta-analysis shows 
Romiplostim offers patients with ITP an effective therapeutic option for 
increasing platelet counts.  
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OBJECTIVES: Rituximab maintenance therapy is associated with significant 
improvement in progression-free and overall survival in patients with NHL. 
However, treatment with rituximab causes considerable costs for health care 
systems. This article provides an overview of Pharmacoeconomical evaluations 
of rituximab and appraises their methodological quality. METHODS: A 
systematic literature search of cost-effectiveness studies on rituximab was 
carried out in several databases, such as PubMed, HTA databases and so on. 
Based on specified inclusion and exclusion criteria, cost-effectiveness studies 
were identified that compared standard chemotherapy with standard 
chemotherapy plus rituximab in patients with a subtype of NHL, including 
diffuse large B-cell lymphoma. The methodological quality of the studies was 
assessed using a quality checklist. RESULTS: The included researches are from 
several countries: the US, UK, Finland, France, Italy and so on. The average ICER 
in the UK is about USD$16318/QALY (GBP10173/QALY), $17688/QALY 
(EUR13275/QALY) in the EU and USD$22461/QALY in the US. All economic 
evaluations reported incremental cost-effectiveness ratios (ICERs) for the add-on 
therapy with rituximab that were below the country-specific thresholds, 
GBP20000~30000/QALY in the UK, EUR30000 ~50000/QALY in the EU and 
USD100000/QALY in the US. CONCLUSIONS: Although the cost of rituximab-
related treatments are relatively higher, they are still cost-effective therapy 
based on the country-specific thresholds.  
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OBJECTIVES: To conduct a systematic review and comparison of pharmacologic 
therapies for treating neuropathic pain (NeP) associated with stroke, HIV, 
trauma, and multiple sclerosis (MS). METHODS: Systematic searches of 
electronic literature databases were conducted to identify randomized, blinded, 
controlled trials of NeP associated with stroke, HIV, trauma, and MS published 
through June 2011. Identified references were screened for inclusion by two 
independent reviewers. Data extracted and evaluated from each study included 
pain severity (11-point numeric rating scale [NRS] or visual analog scale [VAS]), 
proportion of patients achieving 30% and 50% reductions in pain, adverse events 
(AEs), and discontinuations. RESULTS: Eighteen studies met inclusion/exclusion 
criteria. Sample sizes were generally small (11-145 patients) except for 2 HIV, 1 
trauma, and 1 post-stroke pain containing 219-307 patients. Two of the four 
stroke studies presenting mean treatment effects over that of placebo reported 
reductions of -0.2 to -0.3 on NRS for pregabalin, amitriptyline and 
carbamazepine. Of the nine HIV studies, topical capsaicin gave the largest 
treatment effect on the NRS (-2.5). NGX-4010 was the only treatment showing 
higher relative benefit for 30% or 50% pain reduction compared with placebo. Of 
three trauma studies, pregabalin, mexiletine, and gabapentin showed NRS or 
VAS mean pain reductions numerically superior to placebo, although some 
effects were very small. Only pregabalin provided a significant relative benefit of 
30% pain reduction. Two MS studies (<30 patients each) showed mixed efficacy 
for lamotrigine (+0.8 NRS) and levetiracetam (-33.1 VAS). Most studies had 
insufficient data to compare AE risk. Available discontinuation data showed 
similar rates between treatments and placebo. CONCLUSIONS: Studies of NeP 
treatment associated with stroke, HIV, trauma, and MS were few, frequently 
small, and lacked measurements of uncertainty necessary to perform adequate 
comparisons. More and better evaluation of NeP treatment in patients with these 
conditions are needed.  
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OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic connective tissue 
disorder in which the immune system attacks healthy tissue and cells, leading to 
symptoms such as fatigue, muscle pain, and a “butterfly” rash on the nose and 
cheeks. The study objective was to conduct a systematic review and meta-
analysis of new and pipeline B-cell therapies for SLE treatment. METHODS: A 
systematic literature review was conducted in MEDLINE databases from January 
1, 2007 to December 26, 2012 that evaluated primary literature of phase 2 or 
phase 3 studies of B-cell therapies (belimumab, atacicept, epratuzumab, 
tabalumab, blisibimod) in SLE. The search was limited to human studies 
published in English. Descriptive and outcomes data were extracted to assess the 
feasibility of conducting a meta-analysis of comparable endpoints among the 
selected studies. Meta-analysis is in progress. RESULTS: Based on 90 articles 
returned from search terms, 6 articles met search criteria. The 84 excluded 
articles comprised: 29 review articles, 11 phase 1 trials, 14 non-SLE disease 
states, 6 non-human trials, and 24 biologic components of B-cell inhibition. Final 
search results provided 2 studies of pooled analyses of phase 3 belimumab trials. 
Two studies were randomized phase 3 trials of belimumab and 2 studies were 
randomized phase 2 trials of belimumab. The remaining 2 studies were pooled 
sub-analyses of the aforementioned phase 3 trials. Using the criteria set forth by 
Jadad, et al, 4 articles were graded to be excellent (≥66% criteria met), and 2 
articles were rated as poor (<66% criteria met). Feasibility analyses resulted in 2 
studies wherein a meta-analysis could be conducted for SRI response rate, PGA 
score, SF-36 score, and steroid-sparing activity of belimumab vs placebo. 
CONCLUSIONS: Current published literature of phase 2 and phase 3 trials in  
B-cell new product entrants is limited to belimumab for the treatment of SLE.  
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OBJECTIVES: To examine trends in weight control and weight control practices 
among obese persons aged 20 years and older in the U.S from 1999-2010. 
METHODS: Data were analyzed from National Health and Nutrition Examination 
Survey (NHANES) 1999-2010, representing the civilian, noninstitutionalized 
population of the U.S. Obesity was defined as a BMI greater than 30 kg/m2. 
Weight control and weight control practices were based on self-report. All survey 
periods were age-adjusted to the year 2000 US population. RESULTS: Obesity 
awareness decreased from 92.0% (95% CI, 89.9-94.1%) in 1999-2000 to 90.3% (95% 
CI, 89.0-91.6%) in 2009-2010 (P<0.001), it remained stable among men, but 
decreased significantly among women (P=0.01). The percentage of obese persons 
tried to control their weight in the previous 12 months remained stable over 
time, across age, race, and sex groups, including those who tried to lose weight 
(58.6% in 1999-2000 vs. 59.2% in 2009-2010) and those who tried to maintain 
weight (9.1% in 1999-2000 vs. 8.8% in 2009-2010). Among obese persons who tried 
to control their weight, proportion of those who changed their dietary habit 
increased from 48.7% (95%CI, 43.9-53.5%) in 1999-2000 to 63.3% (95%CI, 59.2-
67.4%) in 2009-2010 (P<0.001), proportion of those who increased physical 
activities level increased from 32.6% (95%CI, 28.6-36.6%) in 1999-2000 to 39.3% 
(95%CI, 35.4-43.1%) in 2009-2010 (P=0.05), but proportion of those who combined 
diet control with the higher levels of physical activity did not change 
significantly over time (27.0% in 1999-2000 vs. 33.7% in 2009-2010; P=0.32). 
CONCLUSIONS: Although sixty-eight percent of obese adults reported pursuing 
weight control in NHANES 2009-2010, most of them did not follow 
recommendations for combined caloric restriction with higher levels of physical 
activity.  
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OBJECTIVES: To describe the prevalence of acupuncture and chiropractic use 
among commercially insured patients with rheumatoid arthritis, osteoarthritis, 
neuropathic pain, diabetic peripheral neuropathy or general joint or back pain. 
METHODS: Patients who used acupuncture or chiropractic during 2009-2011 
were identified in the Truven Health Analytics MartketScan Commercial Claims 
and Encounters and Medicare Supplemental Databases. The disease subgroups 
were identified using ICD-9-CM codes. All analyses were conducted using the 
Truven Health Treatment Pathways research tool. RESULTS: Overall, less than 
one-half percent of patients in the MarketScan Research Databases had an 
acupuncture claim between 2009 and 2011. The average age of an acupuncture 
user was 45.2 (SD=14.3) and more than two-thirds (67.7%) were female. 
Acupuncture use was highest among patients with neuropathic pain (1.41%), 
followed by general joint or back pain (1.23%), osteoarthritis (1.10%), rheumatoid 
arthritis (0.99%), and diabetic peripheral neuropathy (0.65%). By comparison, 
7.1% of patients in the dataset had a chiropractic claim between 2009 and 2011. 
Chiropractic users had an average age of 41.9 (SD=16.5) and 56.7% were female. 
Chiropractic use was most prevalent among patients with general joint or back 
pain (21.0%), followed by neuropathic pain (17.4%), osteoarthritis (13.7%), 
rheumatoid arthritis (10.9%), and diabetic peripheral neuropathy (9.7%). 
